The FDA has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone for transplant-ineligible, newly diagnosed multiple myeloma.
Isatuximab (Sarclisa) with bortezomib, lenalidomide, and dexamethasone (VRd) is now an approved option for adults who cannot ...
Zacks.com on MSN2d
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple MyelomaSanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa ...
In addition to other MM indications, Isatuximab's anti-CD38 competitor on the US market, daratumumab (Darzalex — Johnson & Johnson), also carries a first-line indication for transplant-ineligible MM ...
The FDA has approved Sarclisa (isatuximab) as a first-line therapy for blood cancer multiple myeloma as a combination regimen ...
US FDA approves anti-CD38 therapy, Sarclisa in combo with standard-of-care treatment for adult patients with NDMM who are not eligible for transplant: Paris Tuesday, September 24, ...
The 21st annual meeting of the International Myeloma Society takes place September 25-28, 2024, in Rio de Janiero, Brazil.
The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who ...
During a Case-Based Roundtable® event, Andrzej Jakubowiak, MD, PhD, discussed 2 recent trials in multiple myeloma for ...
Multiple myeloma (MM) is a type of blood cancer that typically has no cure. Treatments like medications and stem cell ...
The appeal panel will convene on Monday 23 September 2024 at 10:00am to hear oral representations from the appellants. This will be a virtual appeal hearing webinar via the secure online conferencing ...
The approval is supported by data from the phase 3 IMROZ study which demonstrated superior progression-free survival with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback